Overview

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Status:
Not yet recruiting

Trial end date:
2025-05-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Ustekinumab